secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001558370-22-012231
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Therapeutics prioritizes tau/GBA1/SOD1-ALS pipeline, posts Q2 net loss of $19.1M
--------------------------------------------------------------------------------

- Q2 collaboration revenue $0.7M (down from $1.4M YoY); net loss $19.1M vs $30.1M in Q2 2021.
- Prioritized pipeline: tau antibody for Alzheimer's, GBA1 gene therapy for Parkinson's, SOD1 gene silencing for ALS.
- Identified receptor for TRACER AAV capsid; AAV9-derived capsid shows 50-60x better brain transduction vs AAV9.
- Catherine J. Mackey, Ph.D. (ex-Pfizer) appointed to Board of Directors, effective Aug 15, 2022.
- Cash $148.1M expected to fund operations into 2024; Pfizer option decision by Oct 2022, Novartis by Mar 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000155837022012231/0001558370-22-012231-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000155837022012231/vygr-20220804x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-012231

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer